PDF(Pubmed)
Abstract：
OBJECTIVE: Endometrial cancer (EC) is the predominant malignancy among gynecologic cancers and ranks fourth among all types of cancer. Recently, researchers have focused on the development of new prognostic biomarkers. Subunits of the SWI/SNF protein complex, like the ARID1 and BRG1, have been associated with the development of endometrial cancer. The present study aimed to evaluate the expression patterns of ARID1A and BRG1 in a collection of endometrioid adenocarcinomas of the uterus using immunohistochemistry.
METHODS: The study comprised a total of thirty-three individuals diagnosed with stage I endometrioid endometrial cancer, treated with radical hysterectomy. The histological material was then examined to assess the cytoplasmic and nuclear expression of the proteins.
RESULTS: ARID1A exhibited expression in both the cytoplasm and nucleus of cancer cells, whereas BRG1 was mainly expressed in the nuclei. In addition, ARID1A exhibited a notable decrease in expression in grade 3 histology, with no significant correlation with the depth of myometrial invasion. The reduced expression was highly related to tumor expansion into the endocervix. The findings demonstrated a total absence of ARID1A expression in 27% of endometrioid carcinomas, with a significant reduction in expression in an additional 51% of cancer cells. These findings align with the most recent published data. In contrast, in the current study, BRG1 was rarely down-regulated and was extensively expressed in the majority of endometrioid carcinomas, preventing the possibility of statistical analysis.
CONCLUSIONS: In summary, ARID1A expression loss can be used as a biomarker to guide post-operative therapy; however, further investigation is needed, especially for early-stage endometrial cancer.
METHODS: The study comprised a total of thirty-three individuals diagnosed with stage I endometrioid endometrial cancer, treated with radical hysterectomy. The histological material was then examined to assess the cytoplasmic and nuclear expression of the proteins.
RESULTS: ARID1A exhibited expression in both the cytoplasm and nucleus of cancer cells, whereas BRG1 was mainly expressed in the nuclei. In addition, ARID1A exhibited a notable decrease in expression in grade 3 histology, with no significant correlation with the depth of myometrial invasion. The reduced expression was highly related to tumor expansion into the endocervix. The findings demonstrated a total absence of ARID1A expression in 27% of endometrioid carcinomas, with a significant reduction in expression in an additional 51% of cancer cells. These findings align with the most recent published data. In contrast, in the current study, BRG1 was rarely down-regulated and was extensively expressed in the majority of endometrioid carcinomas, preventing the possibility of statistical analysis.
CONCLUSIONS: In summary, ARID1A expression loss can be used as a biomarker to guide post-operative therapy; however, further investigation is needed, especially for early-stage endometrial cancer.
摘要：
目的：子宫内膜癌（EC）是妇科恶性肿瘤中的主要恶性肿瘤，在所有类型的癌症中排名第四。最近,研究人员专注于开发新的预后生物标志物.SWI/SNF蛋白复合物的亚基，如ARID1和BRG1，已与子宫内膜癌的发展有关。本研究旨在使用免疫组织化学评估子宫内膜样腺癌集合中ARID1A和BRG1的表达模式。
方法：该研究共包括33名被诊断为I期子宫内膜样癌的个体，行根治性子宫切除术。然后检查组织学材料以评估蛋白质的细胞质和核表达。
结果：ARID1A在癌细胞的细胞质和细胞核中均有表达，而BRG1主要在细胞核中表达。此外,ARID1A在3级组织学中表现出明显的表达下降，与肌层浸润深度无显著相关性。表达降低与肿瘤向子宫颈内膜的扩张高度相关。研究结果表明，在27％的子宫内膜样癌中完全不存在ARID1A表达，在另外51%的癌细胞中表达显著降低。这些发现与最新公布的数据一致。相比之下,在目前的研究中，BRG1很少下调，并且在大多数子宫内膜样癌中广泛表达，防止统计分析的可能性。
结论：总之，ARID1A表达缺失可作为指导术后治疗的生物标志物;然而,需要进一步调查，尤其是早期子宫内膜癌。
方法：该研究共包括33名被诊断为I期子宫内膜样癌的个体，行根治性子宫切除术。然后检查组织学材料以评估蛋白质的细胞质和核表达。
结果：ARID1A在癌细胞的细胞质和细胞核中均有表达，而BRG1主要在细胞核中表达。此外,ARID1A在3级组织学中表现出明显的表达下降，与肌层浸润深度无显著相关性。表达降低与肿瘤向子宫颈内膜的扩张高度相关。研究结果表明，在27％的子宫内膜样癌中完全不存在ARID1A表达，在另外51%的癌细胞中表达显著降低。这些发现与最新公布的数据一致。相比之下,在目前的研究中，BRG1很少下调，并且在大多数子宫内膜样癌中广泛表达，防止统计分析的可能性。
结论：总之，ARID1A表达缺失可作为指导术后治疗的生物标志物;然而,需要进一步调查，尤其是早期子宫内膜癌。
